300 A Street
About Silicon TherapeuticsSilicon Therapeutics, the first fully integrated computational drug discovery company, is focused on developing novel medicines for diseases with targets that are currently considered to be challenging for traditional approaches. Our INSITE platform closely represents the real dynamical nature of targets using accurate all-atom simulations, enabling us to discover, design, and optimize compounds for targets that were previously considered "undruggable." Our science, our team, and our mission are focused on applying advanced physics-based computational technologies to build and progress a pipeline of innovative medicines for patients. Silicon Therapeutics is headquartered in Boston, MA, USA with offices in Shanghai, China.
Co-Founder & CEO: Lanny Sun
Co-Founder & Chair of SAB: Lijun Sun, PhD
CSO: Woody Sherman, PhD
Please click here for Silicon Therapeutics' job opportunities.
11 articles about Silicon Therapeutics
Leading computational physics-based platform for design and optimization of small molecules bolsters Roivant's drug discovery capabilities
Distinguished Academic and Industry Leaders in Oncology & Immunology to Advise Company’s Research and Development
Silicon Therapeutics Announces Dosing of First Patient in Phase 1 Open-Label Clinical Trial of SNX281 for Advanced Solid Tumors or Lymphoma
Silicon Therapeutics, a privately-held, integrated therapeutics company with a pioneering platform based on physics-driven molecular simulations, today announced treatment of the first patient with its therapeutic candidate SNX281 in a Phase 1 clinical trial in patients with advanced solid tumors or lymphoma
Silicon Therapeutics , a privately-held, fully integrated drug design, discovery and development company focused on small molecule therapeutics, today introduced an updated corporate website, which reflects the company’s mission, research approach and core values. The new Silicon Therapeutics site more accurately tells the company’s story and clearly highlights the company’s mission to improve the lives of patients by creati
Silicon Therapeutics (SiTX) announced today that Pamela Carroll, Ph.D. has been appointed Chief Business Officer to lead corporate strategy and business development.
Silicon Therapeutics Expands Leadership Team with Key Appointments in Clinical Development and Strategy as well as Computational Physics
Silicon Therapeutics announced three additions to its management team to help lead the company through its next stage of growth. Humphrey Gardner, MD, FCAP has joined the company as Chief Medical Officer; Christopher Borella, PhD, has joined as Vice President, Head of Operations; and Huafeng Xu, PhD, has joined as Chief Technology Officer.
Silicon Therapeutics Expands Board by Naming Roger J. Pomerantz, MD, FACP as Chairman of the Board of Directors and Appointing Mark J. Gilbert, MD as a Board Director
Silicon Therapeutics announced today that it has named Roger J. Pomerantz, MD, FACP, a current member of the Board of Directors, to Chairman and appointed Mark J. Gilbert, MD, to the Board of Directors.
Silicon Therapeutics announced today the appointment of Dr. Christopher Winter as Chief of R&D. Dr. Winter joins Silicon Therapeutics from Sanofi.
Woody Sherman Ph.D, Joins Silicon Therapeutics As CSO, Leading Efforts On Platform Development And Drug Design